Clinical Trials for Brain Tumor

A Single Arm Open Label Study to Determine the Safety and Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Recurrence of Glioma in Patients Who Received a Prior Treatment With 186RNL

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with histologically confirmed recurrent malignant glioma (WHO grade III–IV) who previously received 186RNL, eligible for stereotactic biopsy, are retreated with a single intratumoral infusion of rhenium-186 nanoliposomes via convection-enhanced delivery. 186RNL is a beta-emitting radionuclide encapsulated in nanoliposomes to deliver localized radiation to tumor tissue, with safety, dosimetry, and efficacy (ORR/PFS) assessed; key exclusions include multifocal/leptomeningeal disease and most infratentorial tumors.

ClinicalTrials.gov ID: NCT05460507

Preservation of Cognition and Neuropsychiatric Functioning With Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases: A Pilot Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with solid-tumor brain metastases scheduled for WBRT (MMSE ≥24, KPS ≥70) receive intensity-modulated whole-brain radiotherapy delivering 30 Gy in 10 fractions while selectively sparing the genu of the corpus callosum. Intended for patients without genu involvement (prior SRS allowed, no prior WBRT), this approach aims to preserve cognition and neuropsychiatric function compared with standard WBRT.

ClinicalTrials.gov ID: NCT03223922

Phase I Study of Stereotactic Radiosurgery Dose Escalation for Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with 1–5 previously unirradiated, non–brainstem brain metastases (KPS ≥60) receive stereotactic radiosurgery with dose escalation to one or more eligible lesions, while other lesions (if present) receive standard SRS dosing. Excludes radiosensitive primaries (e.g., small cell, germ cell, lymphoma/leukemia, myeloma) and leptomeningeal disease; evaluates safety/MTD based on grade ≥3 toxicities over 12 weeks.

ClinicalTrials.gov ID: NCT02390518

A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with 5–15 brain metastases (non-hematologic primaries; largest lesion <2.5 cm; ECOG 0–2) are randomized to stereotactic radiosurgery to all lesions versus hippocampal-avoidant whole-brain radiotherapy plus memantine (an NMDA receptor antagonist to mitigate cognitive decline). Excludes prior cranial RT, leptomeningeal disease, lesions near the optic apparatus, certain histologies (germ cell, small cell, lymphoma), and >15 lesions on volumetric MRI.

ClinicalTrials.gov ID: NCT03550391

A Feasibility Study Examining the Use of Non-Invasive Focused Ultrasound (FUS) With Oral Etoposide Administration in Children With Progressive Diffuse Midline Glioma (DMG)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Children and young adults (4–21) with progressive diffuse midline glioma of the pons and/or thalamus (including H3K27M-mutant) receive non-invasive focused ultrasound with microbubbles and neuronavigation to transiently open the BBB at tumor-adjacent sites, combined with concurrent oral etoposide (topoisomerase II inhibitor). Key exclusions include prior etoposide, implanted devices, uncontrolled seizures, significant cardiac/QTc issues, coagulopathy/anticoagulation, and inability to tolerate MRI/anesthesia.

ClinicalTrials.gov ID: NCT05762419

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with measurable brain metastases from TNBC, NSCLC without actionable drivers, or other PD‑1/anti‑angiogenic–sensitive solid tumors (asymptomatic/minimally symptomatic, ECOG 0–1) receive pembrolizumab (PD‑1 inhibitor) plus lenvatinib (VEGFR/FGFR/PDGFR/RET/KIT multikinase inhibitor). Focus is on intracranial efficacy with allowances for untreated or post-radiation progressing brain lesions; excludes leptomeningeal disease and NSCLC with EGFR/ALK/ROS1/RET/NTRK/BRAF V600E/MET alterations.

ClinicalTrials.gov ID: NCT05064280

A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Pediatric and young adult patients (12–25 years) with recurrent or refractory brain tumors of any histology, requiring available tumor tissue for sequencing to design a personalized neoantigen DNA vaccine. Treatment is an intramuscular, electroporation-delivered DNA vaccine encoding patient-specific tumor neoepitopes to induce T-cell responses, given monthly for six priming doses then quarterly boosters.

ClinicalTrials.gov ID: NCT03988283

Phase II Trial of Normal Tissue Sparing Whole Brain Radiation Therapy (NTS-WBRT) in Patients With Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with solid tumor brain metastases requiring whole-brain radiotherapy (no prior WBRT; memantine-naïve; KPS ≥70) receive normal tissue sparing WBRT with optional simultaneous integrated boost plus concurrent memantine to preserve quality of life and neurocognition while maintaining intracranial control. Prior SRS/craniotomy/partial brain RT allowed; excludes leptomeningeal disease.

ClinicalTrials.gov ID: NCT05013892

BrainMet ADePPT (Anticancer Drug Penetration Platform Trial)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with KRAS G12C–mutant brain tumors requiring neurosurgical resection/biopsy (including those with prior CNS radiation/systemic therapy and optional leptomeningeal disease) receive oral sotorasib, either standard dose if DCOI-naïve or continued at prior dose if previously treated. Sotorasib is a selective covalent KRAS G12C inhibitor that locks KRAS in the inactive GDP-bound state; the trial assesses intracranial drug penetration, safety, and preliminary efficacy around the perioperative period.

ClinicalTrials.gov ID: NCT06807619

Phase IIR Trial of Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS (FSRS) for Intact Metastatic Brain Disease (FRACTIONATE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with extracranial primary cancer and at least one intact 2.0–4.0 cm brain metastasis (no prior WBRT, no large brainstem lesions, no leptomeningeal disease) are randomized to single-fraction SRS versus fractionated SRS delivered on Gamma Knife or LINAC. The trial compares local control plus symptomatic radiation necrosis risk (composite endpoint), with secondary outcomes including OS, CNS failure patterns, neurologic death, toxicity, and PROs.

ClinicalTrials.gov ID: NCT05222620